Neurological disorders Cell Models for Research

Neurological disorders are a leading cause of disability and death worldwide. According to the World Health Organization (WHO), neurological disorders affect up to one billion people globally, with conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS) contributing significantly to the global burden of disease. In 2019, the Global Burden of Disease study reported that neurological disorders were responsible for over 9 million deaths and 276 million disability-adjusted life years (DALYs). The prevalence of AD is projected to triple by 2050, reaching 152 million cases, while PD affects over 10 million people. These disorders impose substantial economic burdens, with costs exceeding $1 trillion annually in the United States alone. The clinical impact is profound, as many neurological disorders are progressive and currently lack disease-modifying therapies. The 5-year survival rates for neurodegenerative diseases vary, but for conditions like ALS, the median survival is only 2-5 years from diagnosis. These statistics underscore the urgent need for effective research models to understand disease mechanisms and develop novel therapeutics.

Neurological disorders are ideal for mechanistic studies due to their complex genetic and environmental etiologies. Many disorders exhibit distinct subtypes with varying clinical presentations and genetic underpinnings, such as early-onset versus late-onset Alzheimer's disease. Public datasets, including the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Parkinson's Progression Markers Initiative (PPMI), provide extensive clinical and genomic data. Key open questions include the role of protein aggregation, neuroinflammation, and synaptic dysfunction. Gene-edited cell models, particularly CRISPR-engineered lines, allow researchers to dissect these mechanisms in a controlled environment, enabling the study of specific genetic mutations and their functional consequences. These models are invaluable for target validation and drug discovery, as they can be used to screen potential therapeutics and identify biomarkers.

Several key pathways are implicated in neurological disorders, including:

• • Protein misfolding and aggregation: Accumulation of misfolded proteins (e.g., amyloid-beta, tau, alpha-synuclein) leads to cellular toxicity and neuronal death.
• • Oxidative stress and mitochondrial dysfunction: Impaired mitochondrial function results in increased reactive oxygen species (ROS), causing DNA damage and apoptosis.
• • Neuroinflammation: Chronic activation of microglia and astrocytes contributes to neuronal damage through the release of pro-inflammatory cytokines.
• • Autophagy-lysosomal pathway dysfunction: Defects in autophagy lead to the accumulation of damaged proteins and organelles.

These pathways are interconnected and often converge, making them attractive targets for therapeutic intervention.

Data from TCGA, COSMIC, and ClinVar.

Key signaling networks deregulated in neurological disorders include:

• • MAPK/ERK pathway: Involved in cell survival and differentiation; aberrant activation contributes to neuroinflammation.
• • PI3K/AKT/mTOR pathway: Regulates cell growth and autophagy; dysregulation is linked to Alzheimer's and Parkinson's diseases.
• • Wnt signaling: Plays a role in neurogenesis and synaptic plasticity; altered in schizophrenia and bipolar disorder.
• • NF-κB pathway: Central to inflammatory responses; chronic activation is observed in neurodegenerative diseases.

These networks provide multiple nodes for therapeutic intervention, and gene-edited cell models enable the study of specific pathway components.

Organoids, such as cerebral organoids derived from induced pluripotent stem cells (iPSCs), offer a more physiologically relevant 3D model that recapitulates aspects of brain development and disease. They are particularly useful for studying neurodevelopmental disorders and infectious diseases affecting the brain.

Animal models are essential for studying neurological disorders in a whole-organism context. Common models include:

• • Transgenic mice: Overexpressing mutant human genes (e.g., APP/PS1 for AD, SNCA for PD).
• • Knockout mice: Lacking specific genes (e.g., SOD1 knockout for ALS).
• • Chemically induced models: Using toxins like MPTP to induce parkinsonism.
• • Patient-derived xenograft (PDX) models: For brain tumors, though less common for neurodegenerative diseases.

These models have limitations, including species differences and incomplete recapitulation of human pathology, but remain valuable for preclinical testing.

CRISPR-based gene editing has revolutionized the creation of isogenic cell models for neurological disorders. By introducing specific mutations into a common genetic background (e.g., SH-SY5Y or iPSC-derived neurons), researchers can isolate the effects of a single genetic variant. Examples include:

• • APP knockout cell lines: Used to study amyloid-beta processing.
• • SNCA A53T knock-in lines: Model alpha-synuclein aggregation.
• • LRRK2 G2019S knock-in lines: Investigate kinase activity and mitochondrial dysfunction.

These models are commercially available as sequence-verified, ready-to-use lines, accelerating research. They are essential for drug screening, target validation, and functional genomics.

Gene-edited cell lines enable the validation of genes implicated in neurological disorders. For example, knocking out a candidate gene in a neuronal cell line can reveal its role in cell viability, neurite outgrowth, or protein aggregation. Conversely, introducing a disease-associated mutation (knock-in) can establish causality. These models are also used in CRISPR screens to identify synthetic lethal interactions or modifiers of disease phenotypes.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput drug screening. By comparing the response of mutant and control cells to a library of compounds, researchers can identify drugs that specifically target the mutant phenotype. This approach is particularly useful for developing therapies for genetic forms of Parkinson's disease (e.g., LRRK2 inhibitors) and Alzheimer's disease (e.g., BACE1 inhibitors). Additionally, gene-edited models can be used to study drug resistance mechanisms, such as the upregulation of efflux pumps or alterations in drug targets.

CRISPR-engineered cells are valuable for discovering biomarkers. For example, by comparing the secretome of mutant and wild-type cells, researchers can identify proteins that are differentially released, which may serve as diagnostic or prognostic biomarkers. Synthetic lethality screens using CRISPR can also identify genes whose loss is selectively lethal in disease-associated genetic backgrounds, providing potential therapeutic targets and biomarkers.